Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 163.71 INR 1.65% Market Closed
Market Cap: ₹74.2B

Net Margin

12.9%
Current
Declining
by 1.3%
vs 3-y average of 14.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
12.9%
=
Net Income
₹3.5B
/
Revenue
₹27.3B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
12.9%
=
Net Income
₹3.5B
/
Revenue
₹27.3B

Peer Comparison

Country Company Market Cap Net
Margin
IN
Marksans Pharma Ltd
NSE:MARKSANS
74.2B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Higher than 73% of companies in India
Percentile
73nd
Based on 5 531 companies
73nd percentile
12.9%
Low
-305 007.7% — 2.1%
Typical Range
2.1% — 11.6%
High
11.6% — 1 221 633.3%
Distribution Statistics
India
Min -305 007.7%
30th Percentile 2.1%
Median 5.8%
70th Percentile 11.6%
Max 1 221 633.3%

Marksans Pharma Ltd
Glance View

Marksans Pharma Ltd. is a prominent player in the global pharmaceutical landscape, with its roots deeply embedded in the meticulous world of drug formulation and manufacturing. The company weaves its narrative through a robust portfolio that spans various therapeutic segments, including pain management, oncology, cardiovascular health, and anti-diabetic medications. By navigating the complexities of regulated markets such as the United States, the United Kingdom, and Australia, Marksans has engineered a business model that emphasizes quality, compliance, and innovation. This framework allows the company not only to design and develop a diverse array of generic pharmaceutical products but also to efficiently cater to a global clientele through its cost-effective yet high-quality manufacturing processes. Central to Marksans' success is its strategic integration of research and development with flexible manufacturing capabilities, housed in state-of-the-art facilities across Goa and India. These facilities, certified by leading international regulatory bodies, enable Marksans to maintain a competitive edge in both product delivery and diversification. By leveraging strategic partnerships and continuously expanding its product portfolio, it thrives in the dynamic pharmaceutical market. Revenue generation flows seamlessly through its vertically integrated operations, which streamline the journey from drug conception to distribution. Through these concerted efforts, Marksans not only bolsters its financial standing but also contributes significantly to the broader field of global healthcare, aligning economic performance with a commitment to health and well-being.

MARKSANS Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
12.9%
=
Net Income
₹3.5B
/
Revenue
₹27.3B
What is Marksans Pharma Ltd's current Net Margin?

The current Net Margin for Marksans Pharma Ltd is 12.9%, which is below its 3-year median of 14.2%.

How has Net Margin changed over time?

Over the last 3 years, Marksans Pharma Ltd’s Net Margin has increased from 11.9% to 12.9%. During this period, it reached a low of 11.9% on Sep 30, 2022 and a high of 15.1% on Dec 31, 2023.

Back to Top